Fujirebio Buys Centocor's Diagnostics Division.

Chemical Market Reporter, November, 1998

CENTOCOR INC . will sell its oncology diagnostics business to Fujirebio Inc. of Japan for nearly $37.5 million. The acquisition covers Centocor's in vitro diagnostic operations, which include immunoassays using monoclonal anti body technology. Revenues for Centocor's diagnostics business were $35.4 million in 1997.

Fujirebio, one of the leading diagnostics companies in Japan, will operate the business in Malvern, Pa., and plans to expand its North American operations.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement